medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2013, Número 1

<< Anterior Siguiente >>

Arch Neurocien 2013; 18 (1)


Estado de la investigación sobre la enfermedad de Parkinson en México: de 1988 a 2010

Villar-Velarde A, Rodríguez-Violante M, Cruz-Santillán K, Cervantes-Arriaga A

Idioma: Español
Referencias bibliográficas: 152
Paginas: 27-38
Archivo PDF: 940.08 Kb.


RESUMEN

Objetivo: evaluar la producción científica de manera sistemática sobre enfermedad de Parkinson realizada en México. Material y métodos: se realizó una búsqueda sistemática de las publicaciones realizadas en México en los siguientes sitios: Medline a través de PubMed, Índice Mexicano de Revistas Biomédicas Latinoamericanas (IMBIOMED), Artículos Editados en México sobre información en Salud (ARTEMISA), Scientific Electronic Library Online México (SciELO) y en Medigraphic. Resultados: a través del protocolo de búsqueda en PubMed se obtubieron un total de 113 publicaciones con los criterios establecidos durante el periodo comprendido de enero de 1998 a diciembre de 2010. Se obtuvieron 34 publicaciones adicionales en los demás índices consultados. Aproximadamente el 60% de todas las publicaciones correspondieron a investigación básica. El número de publicaciones se incrementó de forma notoria a partir del 2005. Conclusiones: la investigación en el área básica sobrepasa de forma marcada a la clínica indicando que se requiere fomentar el interés y relevancia de los estudios clínicos en población mexicana con enfermedad de Parkinson. A nivel de publicaciones en revistas nacionales se requiere un mayor número de publicaciones clínicas originales en contraposición al número de revisiones de la literatura existentes al momento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Salleras L. La investigación en poblaciones humanas. Med Clin (Barc) 1989; 92:264-68.

  2. Vallejo M. El diseño de investigación. Una breve revisión metodológica. Arch Cardiol Mex 2002; 72:8-12.

  3. Letelier LM, Manriquez JJ, Rada G. Revisiones sistemáticas y metaanálisis: ¿son la mejor evidencia? Rev Med Chile 2005: 133:246-9.

  4. Rodríguez-A Y, Ruíz I. Sexualidad en la enfermedad de Parkinson. Arch Neurocien (Mex) 1997;2(4):269-73.

  5. Corona T, Wolters ECh. Manejo de las fluctuaciones motoras en la enfermedad de Parkinson. Arch Neurocien (Mex) 1999:4:160-4.

  6. Tarrats-Z RM. Nutrición y enfermedad de Parkinson. Arch Neurocien (Mex) 1999;4(3):139-46.

  7. Hernández-Franco J, Álvarez B, García OM. Rehabilitación del paciente con enfermedad de Parkinson. Arch Neurocien (Mex) 2002;7:213-24.

  8. Bosboom JLW, Corona T, Wolters ECh. Psicosis en la enfermedad de Parkinson. Arch Neurocien 2004;9:25-33.

  9. Florán-Garduño B, Rangel-Barajas C. Activación de receptores dopaminérgicos por L-Dopa. De la acción terapéutica a las discinecias. Rev Biomed 2005;16:273-80.

  10. Góngora-Alfaro JL, Moo-Puc RE, Villanueva-Toledo J, Arankowsky-Sandoval G, Álvarez-Cervera FJ, Pineda-Cortés JC, et al. La cafeína y los antagonistas de los receptores A2 de la adenosina como posibles adyuvantes en la terapia anticolinérgica en la enfermedad de Parkinson. Rev Biomed 2005;16:99-111.

  11. González-Torres LC, Armendáriz-Borunda J. Aspectos inmunológicos en la enfermedad de Parkinson. Arch Neurocien (Mex) 2005;10:168-74.

  12. Arias-Carrión O, Drucker-Colín R. Neurogénesis y enfermedad de Parkinson. Bol Med UAS 2006;14:20-7.

  13. Hernández-Montiel H. Aspectos moleculares y prospectos de terapias en la enfermedad de Parkinson. Bioquimia 2006;31:146-58.

  14. Hernández-Montiel H. Enfermedad de Parkinson: aspectos moleculares, terapia restaurativa y neuroprotección. Arch Neurocien (Mex) 2006;11:100-11.

  15. Moreno-Jiménez S, Celis MA. Radiocirugía con gamma knife para enfermedad de Parkinson. Arch Neurocien (Mex) 2006;11:47-51.

  16. Rodríguez de Romo AC, Hernández-Cruz JI. Parkinson y estereotaxia en el Instituto Nacional de Neurología y Neurocirugía. Arch Neurocien (Mex) 2006;11(2):123-32.

  17. González-López GM, Sosa-Luna CA, Juárez-Maldonado JL, Trejo-Bahena NI, Núñez-Sánchez M, et al. Terapia celular y aplicación de células madre en enfermedad de Parkinson. Neurol Neurocir Psiquiat 2007;40(3):80-91.

  18. Vidrio-Morgado H, Alonso-Vilatela ME, López-López M. Factores genéticos involucrados en la susceptibilidad para desarrollar enfermedad de Parkinson. Sal Men 2007;30 (1):16-24

  19. García S, Sauri-Suárez S, Meza-Dávalos E, Lucino-Castillo J. Perspectiva histórica y aspectos epidemiológicos de la enfermedad de Parkinson. Med Int Mex 2008;24:28-37.

  20. Martínez-Hernández HR, Ríos-Castañeda LC. La sonografía transcraneal, una herramienta útil en el diagnóstico de la enfermedad de Parkinson. Arch Neurocien (Mex) 2008;13 (3):202-7.

  21. Santiago-López D, Rivas-Arancibia S. Estrés oxidativo, metabolitos oxidados de dopamina y enfermedad de Parkinson. Rev Fac Med UNAM 2008;51:104-7

  22. González-López GM, Sánchez-González DJ, Trejo-Bahena NI, Núñez-Sánchez M, Sosa-Luna CA. La terapia celular en la práctica médica. Rev Sanid Milit Mex 2009;63:74-83

  23. Calderón Alvarez-Tostado JL, Bolaños-Jimenez R, Carrillo-Ruiz J, Rivera-Silva G. Interpretación de los principales síntomas motores y no motores en la enfermedad de Parkinson. Rev Mex Neuroci 2010;11(3):218-25.

  24. García S, López B, Meza-Dávalos EG, Villagómez-Ortíz AJ, Coral-Vázquez R. Breve reseña histórica de la enfermedad de Parkinson. De la descripción precipitada de la enfermedad en el siglo XIX, los avances en biología molecular del padecimiento. Med Int Mex 2010;26:350-73.

  25. Martínez-Jurado E, Cervantes-Arriaga A, Rodríguez-Violante M. Calidad de vida en pacientes con enfermedad de Parkinson. Rev Mex Neuroci 2010; 11:480-6.

  26. San-Juan Orta D, del Castillo JD. Sueño y enfermedad de Parkinson. Arch Neurocien (Mex) 2010;15:93-100.

  27. Trujillo Z, Rodríguez Y, Pedraza F, Hernández J, Otero E, Corona T. Rehabilitación en la enfermedad de Parkinson: enfoque multidisciplinario. Arch Inst Nac Neurol Neurocir (Mex) 1995;10(1):33-7.

  28. Cruz-Alcala LE, Vázquez-Castellanos JL. Prevalencia de algunas enfermedades neurológicas en la ciudad de Tepatitlán, Jalisco, México. Rev Mex Neuroci 2002;3:71-6.

  29. Saavedra-Escalona JL, Lupercio-Morales G, Castro-Rodríguez E, Hernández-Franco J. Efecto del tens en el temblor de la enfermedad de Parkinson. Arch Neurocien (Mex) 2005; 10: 133-9

  30. Blaisdell-Vidal C, Carrasco-Vargas H, Gutiérrez-García Z, Elorriaga-Santiago S. Diagnóstico temprano de demencia en pacientes con enfermedad de Parkinson mediante SPECT cerebral. Neurol Neurocir Psiquiat 2006;39:95-9.

  31. Nente-Chávez FA, Campillo-Serrano C, Sosa-Ortíz AL. Efectividad de la terapia electroconvulsiva en el tratamiento de la enfermedad de Parkinson, experiencia en el Instituto Nacional de Neurología y Neurocirugía. Arch Neurocien (Mex) 2007;12:212-20.

  32. Pla-Casamitjana CF, García S, Zárate-Méndez A, Hernández- Salazar M, Sauri-Suárez S, Meza-Dávalos E, et al. Calidad de vida en pacientes con enfermedad de Parkinson y estimulaciíon cerebral profunda. Med Int Mex 2007;23:7-14

  33. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, Corona T. Cálculo de unidades de levodopa en enfermedad de Parkinson. Arch Neurocien (Mex) 2008;14:116-9.

  34. Bertado-Ramírez N, Plascencia-Alvárez N, Quiñones-Aguilar S, Núñez-Orozco L. Datos clave para el diagnóstico clínico de enfermedad de Parkinson. Rev Mex Neuroci 2009;10:340-3.

  35. Hernández-Salazar M, Zárate-Méndez A, Meneses-Luna O, García S, Luján-Guerra JC, Juárez-Cosmes FJ, et al. Blancos estereotácticos más comunes en neurocirugía funcional, experiencia en el centro Médico Nacional “20 de Noviembre”. Arch Neurocien (Mex) 2009;14(2):94-101.

  36. Sandoval LI, Jiménez F, Soto J, Velasco F, Carrillo-Ruiz J, Gómez P, Suárez R. Resultados del tratamiento quirúrgico de la enfermedad de Parkinson en la unidad de neurocirugía funcional, estereotaxia y radiocirugía, del hospital general de México en el periodo de 1992-2009. Rev Mex Neuroci 2010;11(1):20-5.

  37. Martínez-Martí LG, Pavón-Fuentes N, Blacno-Lezcano L, Macías-González R, Castillo-Días L, Rosillo-Martí JC, et al. Estudio morfológico comparative del transplante dopaminérgico en diferentes ganglios basales. Arch Neurocien (Mex) 2006;11:225-31.

  38. García Flores E, Decanini HL, Flores-Salazar M, Lozano Morales E, Zuñiga MC, Martínez-Campos A. Is autologous transplant of adrenal medulla into the striatum an effective therapy for Parkinson´s disease? Prog Brain Res 1990; 82:643-55.

  39. Ostrosky-Solis F. Características neuropsicológicas de la enfermedad de Parkinson. Rev Neurol 2000; 30:788-96.

  40. Segovia J. Gene therapy for Parkinson’s disease: current status and future potential. Am J Pharmacogenomics 2002; 2:135-46.

  41. Drucker-Colín R, Verdugo-Días L. Cell transplantation for Parkinson’s disease: present status. Cell Mol Neurobiol 2004; 24:301-16.

  42. Salamanca-Gómez F. Los genes y la enfermedad de Parkinson. Gac Med Mex 2004;4:475-6.

  43. Lester J, Otero-Siliceo E. Parkinson’s disease and genetics. Neurologist 2006; 12:240-4.

  44. Campos-Romo A. Evaluación de alteraciones motoras en modelos animales de enfermedad de Parkinson. Rev Neurol 2008; 46:167-74.

  45. Halabe-Bucay A. Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson’s disease: a new hypothesis. Ann NY Acad Sci 2008; 1144:237-42.

  46. Vale S. Current management of the cognitive dysfunction in Parkinson’s disease: how far have we come? Exp Biol Med (Maywood) 2008; 233:941-51.

  47. Andrade P, Carrillo-Ruiz JD, Jiménez F. A systematic review of the efficacy of globus pallidus stimulation in the treatment of Parkinson’s disease. J Clin Neurosci 2009; 16:877-81.

  48. Mejía-Toiber J, Castillo CG, Giordano M. Terapia celular y terapia génica ex vivo: avances en el tratamiento de enfermedades del sistema nervioso central. Ren Neurol 2009; 49:483-9.

  49. Góngora-Alfaro JL. La cafeína como un fármaco preventivo de la enfermedad de Parkinson: evidencias epidemiológicas y sustrato experimental. Rev Neurol 2010; 50:221-9.

  50. Vidaltamayo R, Bargas J, Covarrubias L, Hernández A, Galarraga E, Gutiérrez-Ospina G, et al. Stem cell therapy for Parkinson’s disease: a road map for a successful future. Stem Cells Dev 2010;19:311-20.

  51. Ostrosky-Solis F, Quintanar L, Madrazo I, Drucker-Colin R, Franco-Bourland R, Leon-Meza V. Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinson´s disease. Neurology 1988; 38:1442-50.

  52. Macías AE, Valencia A, Vilana M. Long-lasting dementia following brain grafting for the treatment of Parkinson’s disease. Transplantation 1989; 48:348.

  53. Machado-Salas J, Ibarra O, Martínez-Fong D, Cornejo A, Aceves J, Kuri J. Degenerative ultrastructural changes observed in the neuropil of caudate nuclei from Parkinson´s disease patients. Stereotact Funct Neurosurg 1990; 54- 55:297-305.

  54. Madrazo I, Franco-Bourland R, Ostrosky F, Aguilera M, Cuevas CF. Human fetal homograft to the nigrostriatal system for the treatment of Parkinson´s disease. Arch Invest Med 1990; 21:201-7.

  55. Madrazo I, Franco-Bourland, Ostrosky-Solis F, Aguilera M, Cuevas C, Zamorano C. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of parkinsonian subjects. Arch Neurol 1990; 47:1281-5.

  56. Madrazo I, Franco-Bourland R, Ostrosky-Solis F, Aguilera M, Cuevas C, Alvarez F. Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson´s disease: the mexican experience. Prog Brain Res 1990; 82:593-602.

  57. Corona T, Rivera Nava C, Reyes Báez B, Carbajal A. Usefulness of drug holiday in patients with Parkinson’s disease of more than 5 years of development. Rev Invest Clin 1991; 43:334-7.

  58. Madrazo I, Franco-Bourland R, Aguilera M, Ostrosky-Solis F, Madrazo M, Cuevas C, et al. Autologous adrenal medullary, fetal mesencephalic, and fetal adrenal brain transplantation in Parkinson´s disease: a long-term postoperative follow-up. J Neural Transplant Plast 1991; 2:157-64.

  59. Velasco F, Velasco M, Rodríguez Cuevas H, Jurado J, Olvera J, Jiménez F. Autologous adrenal medullary transplants in advanced Parkinson´s disease with particular attention to the selective improvement of symptoms. Stereotact Funct Neurosurg 1991; 57:195-212.

  60. Jimenez F, Velasco F, Velasco M, Velasco AL. Long-term effects of medical and surgical treatments on Parkinson´s disease. Stereotact Funct Neurosurg 1994; 62:85-9.

  61. Corona T, Rivera C, Otero E, Stopp L. A longitudinal study of the effects of an L-dopa holiday on the course of Parkinson´s disease. Clin Neuropharmacol 1995; 18:325-32.

  62. Meléndez-Manzano JA, González-Ortíz J, Meléndez-Manzano E, Lavalle-Martínez J, Schiaffini-Ruiz MC, Vélez-Quintana Roo JO. Cirugía estereotáxica en 4 casos de enfermedad de Parkinson. Rev Invest Clin 1996; 48:449-52.

  63. Rodríguez-Agudelo Y, Corona-Vázquez T, Velázquez-Cardoso J. Evaluación neuropsicológica en pacientes con enfermedad de Parkinson. Rev Invest Clin 1998; 50:197-201.

  64. Drucker-Colin R, Verdugo-Díaz L, Morgado-Valle C, Solís- Maldonado G, Ondarza R, Boll C, et al. Transplant of cultured neuron-like differentiated chromaffin cells in a Parkinson´s disease patient. A preliminary report. Arch Med Res 1999; 30:33-9.

  65. Colorado-Ochoa H. Acatisia secunadria a tolcapone. Reporte de un caso. Gac Méd Méx 2000;136(5):505-9.

  66. Jiménez F, Velasco F, Velasco M, Brito F, Morel C, Marquez I, et al. Subthalamic prelemniscal radiation stimulation for the treatment of Parkinson´s disease: electrophysiological characterization of the area. Arch Med Res 2000; 31:270-81.

  67. Velasco F, Jiménez F, Pérez ML, Carrillo-Ruiz JD, Velasco AL, Ceballos J, et al. Electrical stimulation of the prelemnsical radiation in the treatment of Parkinson´s disease: an old target revised with new techniques. Neurosurgery 2001; 49: 292-306.

  68. Ringman JM, Diaz-Olavarrieta C, Rodríguez Y, Fairbanks L, Cummings JL. The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson´s disease in Mexico. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15:99-105.

  69. Fernandez-Ruiz J, Diaz R, Hall-Haro C, Vergara P, Mischner J, Nuñez L, et al. Normal prism adaptation but reduced aftereffect in basal ganglia disorders using a throwing task. Eur J Neurosci 2003; 18: 689-94.

  70. López-Meza E, Ruiz-Chow A, Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005; 17: 421-2.

  71. Baltasar-Rodríguez LM, Millán-Guerrero RO, Aceves-Themsel R, Isais-Millán S, Delgado-Enciso I. Estudio longitudinal de tres familias con parkinsonismo familiar. Gac Med Mex 2006; 142:387-91.

  72. Jiménez F, Velasco F, Carrillo-Ruiz JD, García L, Madrigal A, Velasco AL, et al. Comparative evaluation of the effects of unilateral lesion versus electrical stimulation of the globus pallidus internus in advanced Parkinson’s disease. Stereotact Funct Neurosurg 2006; 84:64-71.

  73. Carrillo-Ruiz JD, Velasco F, Jiménez F, Velasco AL, Velasco M, Castro G. Neuromodulation of prelemniscal radiations in the treatment of Parkinson’s disease. Act Neurochir Suppl 2007;97: 185-90.

  74. Carrillo-Ruiz JD, Velasco F, Jiménez F, Castro G, Velasco AL, Hernández JA, et al. Bilateral electrical stimulation of prelemniscal radiations in the treatment of advanced Parkinson’s disease. Neurosurgery 2008; 62:347-57.

  75. Merchant H, Luciana M,Hooper C, Majestic S, Tuite P. Interval timing and Parkinson´s disease: heterogeneity in temporal performance. Exp Brain Res 2008; 184:233-48.

  76. Martínez-Rumayor A, Arrieta O, Sotelo J, García E. Female gender but not cigarrete smoking delays the onset of Parkinson´s disease. Clin Neurol Neurosurg 2009; 111:738-41.

  77. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, López-Gómez M, Corona T. Propiedades métricas de intrumentos de disfunción no motora en enfermedad de Parkinson en población mexicana. Rev Invest Clin 2010;62:8-14.

  78. De Font-Réalux Rojas E, Dorazo-Barragán G. Estabilización clínica en enfermedades neurodegenerativas: estudio clínico en fase II. Rev Neurol 2010; 50:520-8.

  79. Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, Corona T. Prevalence of non-motor dysfunction among Parkinson’s disease patients from a tertiary referral center in Mexico City. Clin Neurol Neurosurg 2010; 112:883-5.

  80. Rodríguez-Violante M, Lees AJ, Cervantes-Arriaga A, Corona T, Silveira-Moriyama L. Use of smell test identification in Parkinson’s disease in Mexico: a matched case-control study. Mov Disord 2010.

  81. Drucker-Colín R, García-Hernández F, Mendoza-Ramírez JL, Pacheco-Cano MT, Komisaruk BR. Possible mechanisms of action of adrenal transplants in Parkinson´s disease. Prog Brain Res 1990; 82:509-14.

  82. Machado-Salas J, Cornejo A, Ibarra O, Aceves J, Martínez- Fong D, Huerta G, et al. Multidisciplinary anaylisis of the effectiveness of autologous neural transplant (adrenal medulla) as treatment of Parkinson´s disease. Stereotact Funct Neurosurg 1990; 54-55:306-11.

  83. Rojas P, Altagracia M, Kravsov J, Rios C. Partially protective effect of amantadine in the MPTP model of Parkinson´s disease. Proc West Pharmacol Soc 1992; 35:33-5.

  84. Altagracia M, Rojas P, Kravzov J, Rios C. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson’s disease. Proc West Pharmacol Soc 1993; 36:289.91.

  85. Fernández-Ruiz J, Guzmán R, Martínez MD, Miranda MI, Bermúdez-Rattoni F, Drucker-Colín R. Adrenal medullary grafts restore olfactory deficits and catecholamine levels of 6-OHDA amygdala lesioned animals. J Nerual Transplant Plast 1993; 4:289-97.

  86. García E, Sotelo J. Electroconvulsive shock does not modify striatal contents of dopamine in MPTP-treated mice. Neurochem Res 1993; 18:613-6.

  87. Rojas P, Rios C. Increased striatal lipid peroxidation after intracerebral MPP+ administration to mice. Pharmacol Toxicol 1993; 72:364-8.

  88. Ondarza R, Velasco F, Velasco M, Aceves J, Flores G. Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson´s disease. Stereotact Funct Neurosurg 1994; 62:90-7.

  89. Galarraga E, Bargas J. Firing patterns in substantia nigra compacta identified neurons in vitro. Arch Med Res 1995; 26:191-9.

  90. Drucker-Colin R, Durán-Vázquez A, Salín-Pascual RJ, Verdugo- Díaz L, Mendoza-Ramírez JL, Jiménez-Anguiano A. Rapid eye movement (REM) sleep deprivation in 6-OHDA nigro-striatal lesioned rats with and without transplants of dissociated chromaffin cells. Brain Res 1996; 729:170-5.

  91. Hernández-López S, Flores G, Rosales MG, Sierra A, Martínez- Fong D, Aceves J. Muscarinic antagonists microinjected into the subthalamic nucleus decrease muscular rigidity in reserpinized rats. Neurosci Lett 1996; 213:157-60.

  92. De la Vega MT, Nuñez A, Arias-Montaño JA. Muscarinic M1 and M3 receptors in rat striatum: a binding study. Arch Med Res 1997; 28:493-7.

  93. Verdugo-Diaz L, Morgado-Valle C, Solis-Maldonado G, Drucker- Colin R. Determination of dopamine-releasing protein (DARP) in cerebrospinal fluid of patients with neurological disorders. Arch Med Res 1997; 28:577-81.

  94. Segovia J, Vergara P, Brenner M. Differentiation-dependent expression of transgenes in engineered astrocyte cell lines. Neurosci Lett 1998; 242:172-6.

  95. Segovia J, Vergara P, Brenner M. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Ther 1998; 5:1650-5.

  96. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, Ríos C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson´s disease. Neurosci Lett 1999; 265:155-8.

  97. Flores G, Liang JJ, Sierra A, Martínez-Fong D, Quiron R, Aceves J, et al. Expression of dopamine recpetors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience 1999; 91: 549-56.

  98. Trejo F, Vergara P, Brenner M, Segovia J. Gene therapy in a rodent model of Parkinson’s disease using differentiated C& cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci 1999; 65:483-91

  99. Anaya-Martínez V, Montiel-Flores E, Espinosa-Villanueva J, García-Hernández F. Effects of graft placement site on the survival of adrenal medulla transplants into the brain and its relation with the recovery of motor function. Arch Med Res 2000;31:551-7.

  100. Corona-Morales AA, Castell A, Zhang L. L-dopa-induced neurotoxic and apoptotic changes on cultured chromaffin cells. Neuroreport 2000; 11:503-6.

  101. Cortez N, Trejo F, Vergara P, Segovia J. Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavorial recovery in experimental parkinsonism. J Neurosci Res 2000;59:39-46.

  102. Zhang L, Castell A, Avila E, Drucker-Colín R, Escobar A. Immunocytochemical, ultrastructural and neurochemical evidences on synaptogenesis and dopamine release of rat chromaffin cells co-cultured with striatal neurons. J Neuropathol Exp Neurol 2000; 59:170-4.

  103. Galvan A, Floran B, Erlij D, Aceves J. Intrapallidal dopamine restores motor deficits induced by hidroxydopamine in the rat. J Neural Transm 2001; 108:153-66.

  104. Ortiz GG, Crespo-López ME, Morán-Moguel C, García JJ, Reiter RJ, Acuña-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett 2001; 22:101-8.

  105. Florán B, Barajas C, Florán L, Erlij D, Aceves J. Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulate and motor behavior in the rat. Neuroscience 2002;115:743-51.

  106. Corona-Morales AA, Castell A, Escobar A, Drucker-Colin R, Zhang L. Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity. J Neurosci Res 2003;71:121-6.

  107. Guzmán JN, Hernández A, Galarraga E, Tapia D, Laville A, Aceves J, et al. Dopaminergic modulation of axon collaterals interconnecting spin neurons of the rat striatum. J Neurosci 2003;8931-40.

  108. García-Ramírez M, Aceves J, Arias-Montaño JA. Intranigral ijection of the H3 agonist immepip and systemic apomorphine elicit ipsilateral turning behavior in naïve rats but reduce contralateral turning in hemiparkinsonian rats. Behav Brain Res 2004;154:409-15.

  109. Moo-Puc RE, Villanueva-Toledo J, Arankowsky-Sandoval G, Alvarez-Cervera F, Góngora-Alfaro JL. Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats. Neurosci Lett 2004; 367: 327-31.

  110. Alvarez-Cervera FJ, Villanueva-Toledo J, Moo-Puc RE, Heredia- López FJ, Alvarez-Cervera M, Pineda JC, et al. A novel automated rat catalepsy bar test system based on a RISC microcontroller. J Neurosci Methods 2005; 146:76-83.

  111. Avila-Costa MR, Colín-Barenque L, Montile-Flores E, Aley- Medina P, Valdez AL. Bromocriptine treatment in a murine Parkinson´s model: ultrastructural evaluation after dopaminergic deafferentation. Int J Neurosci 2005;115:851-9.

  112. Anaya-Martínez V, Martínez-Marcos A, Martínez-Fong D, Aceves J, Erij D. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior. Neuroscience 2006; 143:477-86.

  113. Angoa-Pérez M, Jiang H, Rodríguez AI, Lemini C, Levine RA, Rivas-Arancibia S. Estrogen counteracts ozone-induced oxidative stress and nigral neuronal death. Neuroreport 2006; 17: 629-33.

  114. Chamorro G, Pérez-Albiter M, Serrano-García N, Mares- Sámano JJ, Rojas P. Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Nutr Neurosci 2006;9:207-12.

  115. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martínez V, Flores G, Navarro-Quiroga I, et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 2006; 14:857-65.

  116. Ramírez-Jirano LJ, Ruiz-Sandoval JL, Jiménez-Gil FJ, Ramírez- Vega J, Vargas-Frutos E, Gallegos-Arreola MP. Polimorfismo - 116C-G del gen alfa-sinucleína en pacientes con enfermedad de Parkinson. Salud Publica Mex 2006; 48:289-90.

  117. Silva I, Cortes H, Escartín E, Rangel C, Florán L, Erlij D, et al. L-Dopa inhibits depolarization-induced [3H] GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like recepetors. J Neural Transm 2006; 113:1847-53.

  118. Bata-García JL, Villanueva-Toledo J, Gutiérrez-Ospina G, Alvarez-Cervera FJ, Heredia-López FJ, Góngora-Alfaro JL. Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl. Pharmacol Biochem Behav 2007; 86:68-78.

  119. Diaz NF, Guerra-Ariza C, Díaz-Martínez NE, Salazar P, Molina- Hernández A, Camacho-Arroyo I, et al. Changes in the content of estrogen alpha and progesterone receptors during differentiation of mouse embryonic stem cells to dopamine neurons. Brain Res Bull 2007; 73:75-80.

  120. Guerrero-Cázares H, Alatorre-Carranza M del P, Delgado-Rizo V, Duenas-Jimenez JM, Mendoza-Magana ML, Morales- Villagran A, et al. Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells. Brain Res Bull 2007; 74:113-8.

  121. Ibañez-Sandoval O, Carrillo-Reid, Galarraga E, Tapia E, Mendoza E, Gomora JC, Aceves J, et al. Bursting in substantia nigra pars reticulata neurons in vitro: possible relevance for Parkinson disease. J Neurophysiol 2007; 98:2311-23.

  122. Lopez M, Guerrero J, Yescas P, Boll MC, Familiar I, Ochoa A, et al. Apoliprotein E epsilon4 alllele is associated with Parkinson disease risk in a Mexican mestizo population. Mov Disord 2007; 22:417-20.

  123. Ramírez-Jirano LJ, Ruiz-Sandoval JL, Jiménez-Gil FJ, Ramírez- Vega J, Vargas-Frutos E, Gallegos-Arreola MP. Frecuencia del polimorfismo IVS4+66A-G en el gen alfa-sinucleína en pacientes con enfermedad de Parkinson del noroccidente de México. Rev Neurol 2007; 44:15-7.

  124. Solís O, Limón DI, Flores-Hernández J, Flores G. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson´s disease. Synapse 2007; 61:450-8.

  125. Boll MC, Alcaraz-Zubeldia M, Montes S, Ríos C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008; 33:1717-23.

  126. Ordoñez-Librado JL, Gutiérrez-Valdez AL, Colin-Barenque L, Anaya-Martínez V, Diaz-Bech P, Avila-Costa MR. Inhalation of divalent and trivalent manganese mixture induces a Parkinson’s disease model: inmunocytochemical and behavioral evidences. Neuroscience 2008; 155:7-16.

  127. Pérez-Neri I, Méndez-Sánchez I, Montes S, Ríos C. Acute dehydroepiandrosterone treatment exerts different effects on dopamine and serotonin turnover ratios in the rat corpus striatum and nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1584-9.

  128. Rangel-Barajas C, Silva I, García-Ramírez M, Sánchez-Lemus E, Floran L, Aceves J, et al. 6-OHDA-inudced hemiparkinsonism and chronic L-dopa treatment increase dopamine D1- stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulate of the rat. Neuropharmacology 2008; 55:704-11.

  129. Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine induced parkinsonism in mice: a role of oxidative stress. Eur J Neurosci 2008; 28:41-50.

  130. Alcaraz-Zubeldia M, Boll-Woehrlen MC, Montes-López S, Pérez-Severiano F, Martínez-Lazcano J, Díaz-Ruiz A, et al. Copper sulfate prevents tyrosine hydroxilase reduced activity and motor deficits in Parkinson’s disease model in mice. Rev Invest Clin 2009;61(5):405-11

  131. Campos-Romo A, Ojeda-Flores R, Moreno-Briseño P, Fernández-Ruiz J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the Hallway Task. J Neuorsci Methods 2009; 177:261-8.

  132. Díaz NF, Días-Martínez NE, Camacho-Arroyo I, Velasco I. Estradiol promotes proliferation of dopaminergic precursors resulting in a higher proportion of dopamine neurons derived from mouse embryonic stem cells. Int J Dev Neurosci 2009; 27:493-500.

  133. Díaz NF, Díaz-Martínez NE, Velasco I, Camacho-Arroyo I. Progesteron increases dopamine neuron number in differentiating mouse embryonic stem cells. J Neuroendocrinol 2009;21:730-6.

  134. Gallegos-Arreola MP. Figueroa LE, Ortíz GG, Ramírez-Vega J, Ruíz Sandoval JL, et al. Apolipoprotein E genotypes in Mexican patients with Parkinson’s disease. Dis Markers 2009;27: 225-30.

  135. Góngora-Alfaro JL, Moo-Puc RE, Villanueva-Toledo JR, Alvarez- Cervera FJ. Bata-García JL, Heredia-López FJ, et al. Longlasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine. Neurosci Lett 2009; 463:210-4.

  136. Mendieta L, Venegas B, Moreno N, Patricio A, Martínez I, Aguilera J, et al. The carboxyl-terminal domain of the heavy chain of tetanus toxin prevents dopaminergic degeneration and improves motor behavior in rats with striatal MPP(+)- lesions. Neurosci Res 2009;65:98-106.

  137. Orozco-Barrios CE, Battaglia-Hsu SF, Arango-Rodríguez ML, Ayala-Davila J, Chery C, Alberto JM. Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra. PLoS One 2009;4:e8268.

  138. Pérez-Neri I, Montes S, Ríos C. Inhibitory effect of dehydroepiandrosteron on brain monoamine oxidase activity: in vivo and in vitro studies. Life Sci 2009;85:652-6.

  139. Prieto GA, Pérez-Burgos A, Fiordelisio T, Salgado H, Galarraga E, Drucker-Colin R, et al. Dopamine D82)-class receptor supersenitivity as reflected in Ca2+ current modulation in neostratial neurons. Neurosciene 2009;164:345-50.

  140. Rojas P, Montes S, Serrano-García N, Rojas-Castañeda J. Effect of EGb761 supplementation on the content of copper in mouse brain in an animal model of Parkinson’s disease. Nutrition 2009; 25:482-5.

  141. Rubio-Osornio M, Montes S, Pérez-Severiano F, Aguilera P, Floriano-Sánchez E, Monroy-Noyola A, et al. Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats. Neurochem Int 2009; 54:447-51.

  142. Jáidar O, Carrillo-Reid L, Hernández A, Drucker-Colín R, Bargas J, Hernández-Cruz A. Dynamics of the Parkinsonian striatal microcircuit: entr ainment into a dominant network state. J Neurosci 2010; 30:11326-36.

  143. Martínez HR, González-González H, Cantú-Martínez L, Rangel- Guerra R, Hernández-Castillo CD, et al. Parkin-coding polymorphism are not associated with Parkinson’s disease in a population from northeastern Mexico. Neurosci Lett 2010;468:264-6.

  144. Ordoñez-Librado JL, Anaya-Martínez V, Gutierrez-Valdez AL, Montiel-Flores E, Corona DR, Martínez-Fong D, et al. L-Dopa treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model. Neurosci Lett 2010; 471:79-82.

  145. Querejeta E, Martínez-Romero B, Miranda JE, Delgado A. Modulation of the striato-pallidal pathway by adenosine A2a receptors depends on dopaminergic striatal input. Brain Res 2010; 149-137-42.

  146. Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J, Carrillo-Mora P, González-Herrera IG, et al. Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 2010;7.

  147. Tamaríz E, Díaz-Martínez NE, Díaz NF, García-Peña CM, Velasco I, et al. Axon responses of embryonic stem cell-derived dopamine neurons to semaphorins 3A and 3C. J Neurosci Res 2010; 88:971-80.

  148. Tobón-Velasco JC, Carmona-Aparicio L, Ali SF, Santamaría A. Biomarkers of cell damage induced by oxdative stress in Parkinson’s disease and related models. Cent Nerv Syst Agents Med Chem 2010.

  149. Yescas P, López M, Monroy N, Boll MC, Rodríguez-Violante M, et al. Low frequency of common LRKK2 mutations in Mexican patients with Parkinson’s disease. Neurosci Lett 2010; 485:79-82.

  150. Vasconcelos SM, Sorenson NM, Santana MC, Batista PD. Researchers’ writing competence: a bottlenech in the publication of Latin-American science? EMBO Rep 2008; 9:700-2.

  151. Hirsch JE. An index to quantify an individal’s scientific research output. Proc Natl Acad Sci USA 2005; 102: 16569-72.

  152. Hermes-Lima M, Alencastro AC, Santos NC, Navas CA, Beleboni RO. The relevance and recognition of Latin America science. Introduction to the fourth issue of CBP-Latin America. Comp Biochem Physiol Toxicol Pharmacol 2007; 146:1-9.




2020     |     www.medigraphic.com